COMPLEX: Investing in the share market is an inexact science, and biotech stocks can add a further layer of complexity to the formula.

Bitter pill for investors’ pain

Investors scorched by the share price collapse of local pharmaceutical development company pSivida can take some heart from a recent report suggesting they are not alone when it comes to understanding precisely how some drug and biotechnology products actually work.


(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

BNiQ Disclaimer